Capricor is gearing up to study the cell therapy in a pivotal Phase III trial in Duchenne muscular dystrophy (DMD). Nippon Shinyaku, which does business in the U.S. through subsidiary NS Pharma, has inked an up-to-$735 million exclusive U.S. commercialization and distribution agreement for CAP-1002 in DMD. Capricor President and CEO Linda Marbán, PhD, told GEN Edge her company first met with representatives of NS Pharma two years ago at the J.P. Morgan 38th Healthcare Conference . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post Same Drug, New Partner: Capricor in Up-to-$735M Deal for DMD Cell Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.